Starting July 1, 2026, eligible Medicare beneficiaries can access Wegovy or Zepbound for a flat $50 monthly copay through a new CMS demonstration program. Here's the exact BMI eligibility criteria, what plans qualify, how the application actually works, and the gaps nobody else is explaining clearly.
The headline: Starting July 1, 2026, the Medicare GLP-1 Bridge — a temporary CMS demonstration program — allows eligible Medicare Part D beneficiaries to access Wegovy or Zepbound for weight loss at a flat $50 monthly copay, down from retail prices of $1,000+/month. The program runs through December 31, 2027.
What the Medicare GLP-1 Bridge actually is
Medicare has historically been legally prohibited from covering medications used purely for weight loss. The GLP-1 Bridge is a temporary demonstration program designed by CMS specifically to close that gap while a longer-term solution — called the BALANCE Model — is finalized for 2027 and beyond.
The program operates outside the standard Part D benefit structure. Instead of going through your regular Part D plan's normal cost-sharing rules (deductible, coverage gap, catastrophic phase), the Bridge uses a separate central processor with a fixed $50 copay regardless of where you are in your plan year.
$50
Flat monthly copay, regardless of Part D phase
CMS confirmed
$245
Negotiated net price manufacturers provide the drug at
CMS pays the remainder
Jul 1 — Dec 31 2027
Program duration (already extended once)
CMS demonstration period
Exact BMI and clinical eligibility criteria
This is the part most coverage of this program gets vague on. The actual criteria, confirmed by CMS and reported across multiple legal and healthcare policy sources, are:
- BMI of 35 or greater — qualifies on its own, no additional condition required
- BMI of 30 or greater — plus a diagnosis of heart failure, uncontrolled hypertension, or chronic kidney disease
- BMI of 27 or greater — plus a diagnosis of pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease
Clinical criteria are assessed at the time you first started GLP-1 therapy — including if you started before enrolling in Medicare Part D or before the July 1, 2026 Bridge launch date. This matters: if you're already on Wegovy or Zepbound through another payment method, you may already meet criteria based on your original starting BMI, even if you've since lost weight.
Already lost weight on a GLP-1? CMS has clarified that eligibility is based on the clinical criteria at the time therapy was initiated — not your current BMI. If you started above the threshold and have since lost weight, you generally remain eligible. Confirm this directly with your prescribing physician's documentation.
Which medications and plans are covered
Updated June 2026: Foundayo (orforglipron), the new oral GLP-1 approved April 1, 2026, has been confirmed as Bridge-eligible alongside Wegovy and Zepbound.
Read our full Foundayo review → Note that Mounjaro is
not included in the Bridge, because it is FDA-approved for type 2 diabetes rather than weight loss — only the weight-loss-indicated medications (Wegovy, Zepbound, Foundayo) qualify.
| Factor | Details |
|---|
| Eligible medications | Wegovy (injection and oral tablet), Zepbound (KwikPen), Foundayo (orforglipron, oral) |
| Eligible plan types | Standalone Part D (PDP) or Medicare Advantage with drug coverage (MA-PD) |
| Special Needs Plans (SNPs) | Eligible to participate |
| Dually-eligible beneficiaries | Eligible if enrolled in a qualifying Part D plan type |
| Medicare Advantage WITHOUT drug coverage | Not eligible — must switch plans |
| Private fee-for-service, PACE, cost contract plans | Not eligible (PACE has separate rules — see below) |
The gap almost nobody explains clearly: Low-Income Subsidy does NOT apply
Important limitation: If you qualify for Extra Help (the Part D Low-Income Subsidy), those cost-sharing reductions do not reduce the $50 Bridge copay. The $50 is the floor regardless of income-based subsidies you may otherwise qualify for elsewhere in your Part D coverage. KFF has flagged this as a potential barrier for lower-income beneficiaries for whom even $50/month may be a genuine financial obstacle.
Similarly, manufacturer coupons and additional discounts cannot be stacked on top of the $50 copay to reduce it further — $50 is both the floor and ceiling under this specific program.
How the application process actually works
There is no patient-facing application form. The process runs entirely through your physician and the pharmacy:
What actually happens, step by step:
Your physician determines you meet the BMI and clinical criteria above
Your physician submits a prior authorization request to the central Bridge processor (not your regular Part D plan)
Once approved, your pharmacy processes the claim using the Bridge-specific BIN (028918) and PCN (MEDDGLP1BR) — not your standard Part D insurance card numbers
You pay $50 at pickup, regardless of your deductible status or coverage phase
If your pharmacy tries to run the claim through your regular Part D benefit instead of the Bridge-specific processor, it may be rejected or charged at standard cost-sharing rates. Confirm with your pharmacist that they're processing it correctly through the Bridge.
Timeline
March 3, 2026 — CMS released official FAQ guidance
Detailed eligibility, BIN/PCN, and operational rules confirmed.
Spring 2026 — Additional provider process details released
CMS provided further operational guidance to physicians and pharmacies ahead of launch.
July 1, 2026 — Bridge program launches
Eligible beneficiaries can begin accessing Wegovy and Zepbound at the $50 copay.
Open enrollment 2026 (for 2027 plans)
Beneficiaries may need to switch to a Part D plan participating in the BALANCE Model to maintain GLP-1 access into 2027.
December 31, 2027 — Bridge program concludes
Transition to the longer-term BALANCE Model, contingent on enough Part D plans opting in.
What if you're not eligible or $50/month is still too much
- Switch plans during open enrollment if you're on a Medicare Advantage plan without drug coverage, or a non-participating plan type.
- Manufacturer patient assistance programs from Novo Nordisk and Eli Lilly may offer additional support — verify directly, as these programs may exclude government-insurance beneficiaries.
- Compounded GLP-1 through telehealth remains a separate, parallel option outside Medicare entirely, typically $99-199/month, that doesn't depend on Bridge eligibility, plan type, or BMI thresholds at all.
✅ The bottom line
If you're a Medicare beneficiary who meets the BMI/clinical criteria and is enrolled in a qualifying Part D or MA-PD plan, the Bridge program is a genuinely significant cost reduction — from $1,000+/month down to $50. Talk to your physician now, before July 1, so the prior authorization is ready to submit the moment the program goes live. If you don't qualify, or $50/month is still a barrier, compounded GLP-1 through telehealth remains available as a parallel path with no Medicare-specific restrictions.
Not eligible for the Bridge, or want an option that starts today?
DirectMeds offers physician-supervised compounded semaglutide from $99/month and tirzepatide from $149/month — available now, independent of Medicare plan type or BMI tier restrictions.
Check eligibility at DirectMeds →
Frequently asked questions
Who is eligible for the Medicare GLP-1 Bridge program?
Eligibility requires a BMI of 35 or greater on its own, OR a BMI of 30+ with heart failure, uncontrolled hypertension, or chronic kidney disease, OR a BMI of 27+ with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease. You must also be enrolled in a standalone Medicare Part D plan or a Medicare Advantage plan with drug coverage (MA-PD) in 2026. Clinical criteria are assessed at the time you first started GLP-1 therapy, not necessarily your current BMI.
When does the Medicare GLP-1 Bridge program start?
The program begins July 1, 2026 and runs through December 31, 2027. It was originally designed as a six-month program through December 2026 but has already been extended through 2027. It serves as a transition to the longer-term BALANCE Model beginning in 2027.
How much does the Medicare GLP-1 Bridge copay cost?
Eligible beneficiaries pay a flat $50 monthly copay for Wegovy or Zepbound, regardless of which phase of their Part D benefit they're in (deductible, initial coverage, coverage gap, or catastrophic). This $50 is both the floor and ceiling — Low-Income Subsidy (Extra Help) reductions do not apply to reduce it further, and manufacturer coupons cannot be stacked on top of it.
Does the Medicare GLP-1 Bridge work with Low-Income Subsidy (Extra Help)?
No. CMS has confirmed that Part D Low-Income Subsidy cost-sharing reductions do not apply to the Bridge program's $50 copay. This has been flagged by health policy researchers as a potential barrier for lower-income beneficiaries who may otherwise rely on Extra Help to afford their medications.
What if my Medicare Advantage plan doesn't include drug coverage?
You are not eligible for the Bridge program with a Medicare Advantage plan that lacks prescription drug coverage. You would need to either switch to a Medicare Advantage plan that includes drug coverage (MA-PD) or enroll in a standalone Part D plan during the next open enrollment period to participate.